EP1085892A2 - Impfstrategie zur vorbeugung und behandlung von krebs - Google Patents
Impfstrategie zur vorbeugung und behandlung von krebsInfo
- Publication number
- EP1085892A2 EP1085892A2 EP99930206A EP99930206A EP1085892A2 EP 1085892 A2 EP1085892 A2 EP 1085892A2 EP 99930206 A EP99930206 A EP 99930206A EP 99930206 A EP99930206 A EP 99930206A EP 1085892 A2 EP1085892 A2 EP 1085892A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- mhc
- therapeutic
- immunogenic
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 75
- 238000002255 vaccination Methods 0.000 title description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 180
- 239000000427 antigen Substances 0.000 claims abstract description 72
- 108091007433 antigens Proteins 0.000 claims abstract description 70
- 102000036639 antigens Human genes 0.000 claims abstract description 70
- 230000002163 immunogen Effects 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 21
- 230000008073 immune recognition Effects 0.000 claims abstract description 18
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims abstract description 12
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 210000001163 endosome Anatomy 0.000 claims abstract description 5
- 230000004075 alteration Effects 0.000 claims abstract description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 33
- 229960005486 vaccine Drugs 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 230000032258 transport Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 4
- 108010017842 Telomerase Proteins 0.000 claims description 4
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 abstract description 13
- 108091054437 MHC class I family Proteins 0.000 abstract description 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract description 8
- 210000000987 immune system Anatomy 0.000 abstract description 7
- 238000011068 loading method Methods 0.000 abstract description 6
- 210000003712 lysosome Anatomy 0.000 abstract description 2
- 230000001868 lysosomic effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 42
- 238000001727 in vivo Methods 0.000 description 21
- 230000003053 immunization Effects 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 201000001441 melanoma Diseases 0.000 description 16
- 108091008874 T cell receptors Proteins 0.000 description 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000037452 priming Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 238000011105 stabilization Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- -1 Trp Chemical class 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010036616 P18-I10 peptide Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 108700025333 4'-azido-Phe(6)- herpes simplex virus H2 (6-15) Proteins 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- 229940122450 Altered peptide ligand Drugs 0.000 description 1
- BMNVSPMWMICFRV-DCAQKATOSA-N Arg-His-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CN=CN1 BMNVSPMWMICFRV-DCAQKATOSA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 101710091881 GTPase HRas Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000946837 Homo sapiens Cell division cycle protein 27 homolog Proteins 0.000 description 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010075205 OVA-8 Proteins 0.000 description 1
- 241000283222 Physeter catodon Species 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000043700 human CDC27 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the heteroclitic peptide in accordance with the invention can also be one in which the MHC-binding domain binds to enhanced affinity to an MHC Class II molecule on an antigen presenting cell, and the immune-recognition domain binds to the TCR of a CD4+ T cell.
- Identification of target peptides which will generally be 9 to 14 amino acids in length, is done in substantially the same manner as for target peptides which bind to MHC-Class I molecules.
- Example 1 Heteroclitic vaccination in an engineered lymphoma model
- peptide immunogenicity correlates to peptide binding.
- bm8 mice respond to peptide priming by SSI (squares) and SEI (circles), both of which bind well to K bm8 (16). Results are representative of at least 25 mice/strain tested in at least six independent experiments. Methods and data representation were as described in A. However, SEI was a good immunogen in B6.C-FI-2.
- b 8 (bm8) mice (Fig. IB, circles), that express a natural K b variant, K bmS . This class I molecule has an E24 ⁇ S mutation that enables strong SEI binding (16).
- SSI The natural viral peptide from which H2E was derived, SSI (SSIEFARL [Seq. ID No. 10], also referred to as HSV-8), differs from SEI by having a serine (P2S) instead of the glutamic acid (P2E) in position 2.
- P2S serine
- P2E glutamic acid
- SSI would be predicted to remove the electrostatic repulsion between the peptide and K b . Indeed, SSI bound a hundred fold better than SEI to K b
- RMA-S has a chemically induced deletion of one of its transporter associated with peptide processing (TAP) genes, Tap-2.
- TAP peptide processing
- This deletion prevents the vast majority of cytosolically processed peptides from entering the ER and binding to empty class I molecules, which leads to decreased expression of stable class I molecules at the surface of RMA-S cells.
- the TAP defect was circumvented using a minigene encoding an endoplasmic reticulum insertion sequence (ERIS) (17) followed by the SEI peptide. Fusion proteins encoded by such ERIS- containing minigenes were previously shown to insert the attached class I binding peptides into the ER, thereby bypassing the TAP defect and partially restoring the surface expression of pep lass I (17,18).
- ERIS endoplasmic reticulum insertion sequence
- RS-SEI RMA-S cells transfected with the pERIS-SEI plasmid
- RS-Null cells transfected with the "empty" control plasmid, pcDNA3
- the mean relative K b fluorescence intensity for RS-SEI was 123 as compared to only 79 for RS-null.
- TRP2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8905598P | 1998-06-12 | 1998-06-12 | |
| US89055P | 1998-06-12 | ||
| US10633998P | 1998-10-30 | 1998-10-30 | |
| US106339P | 1998-10-30 | ||
| PCT/US1999/013146 WO1999063945A2 (en) | 1998-06-12 | 1999-06-11 | Vaccination strategy to prevent and treat cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1085892A2 true EP1085892A2 (de) | 2001-03-28 |
| EP1085892A4 EP1085892A4 (de) | 2002-07-17 |
Family
ID=26780171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99930206A Withdrawn EP1085892A4 (de) | 1998-06-12 | 1999-06-11 | Impfstrategie zur vorbeugung und behandlung von krebs |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1085892A4 (de) |
| CA (1) | CA2331378A1 (de) |
| WO (1) | WO1999063945A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| KR20000048820A (ko) | 1996-10-01 | 2000-07-25 | 게론 코포레이션 | 텔로머라제 역전사 효소 |
| US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| AU3456099A (en) | 1998-03-31 | 1999-10-18 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
| AU2001241533A1 (en) | 2000-02-15 | 2001-08-27 | The Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| DK1311542T3 (da) | 2000-08-21 | 2008-11-10 | Apitope Technology Bristol Ltd | Tolerogene peptider |
| WO2002066515A1 (en) * | 2001-02-23 | 2002-08-29 | Institut Pasteur | Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029193A2 (en) * | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
-
1999
- 1999-06-11 CA CA002331378A patent/CA2331378A1/en not_active Abandoned
- 1999-06-11 EP EP99930206A patent/EP1085892A4/de not_active Withdrawn
- 1999-06-11 WO PCT/US1999/013146 patent/WO1999063945A2/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029193A2 (en) * | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
Non-Patent Citations (9)
| Title |
|---|
| BAKKER ALEXANDER B H ET AL: "Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope." INTERNATIONAL JOURNAL OF CANCER, vol. 70, no. 3, 1997, pages 302-309, XP000917224 ISSN: 0020-7136 * |
| DYALL R ET AL: "HETEROCLITIC IMMUNIZATION INDUCES TUMOR IMMUNITY" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 9, 2 November 1998 (1998-11-02), pages 1553-1561, XP002947142 ISSN: 0022-1007 * |
| KAWAKAMI Y ET AL: "HUMAN MELANOMA ANTIGENS RECOGNIZED BY T LYMPHOCYTES" KEIO JOURNAL OF MEDICINE, TOKYO, JP, vol. 45, no. 2, 1996, pages 100-108, XP000917151 ISSN: 0022-9717 * |
| LIPFORD G B ET AL: "Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6." IMMUNOLOGY, vol. 84, no. 2, 1995, pages 298-303, XP000493663 ISSN: 0019-2805 * |
| OVERWIJK WILLEM W ET AL: "gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 2, 20 July 1998 (1998-07-20), pages 277-286, XP002938364 ISSN: 0022-1007 * |
| See also references of WO9963945A2 * |
| TOPALIAN SUZANNE L ET AL: "Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 5, 1996, pages 1965-1971, XP000645355 ISSN: 0022-1007 * |
| TOURDOT S ET AL: "Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, no. 5, 1 September 1997 (1997-09-01), pages 2391-2398, XP002170618 ISSN: 0022-1767 * |
| VAN DER BURG SJOERD J ET AL: "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability." JOURNAL OF IMMUNOLOGY, vol. 156, no. 9, 1996, pages 3308-3314, XP002197979 ISSN: 0022-1767 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2331378A1 (en) | 1999-12-16 |
| EP1085892A4 (de) | 2002-07-17 |
| WO1999063945A3 (en) | 2000-03-02 |
| WO1999063945A2 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dyall et al. | Heteroclitic immunization induces tumor immunity | |
| EP2089423B1 (de) | Antigenspezifische multi-epitop-impfstoffe | |
| US8470560B2 (en) | CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines | |
| CA2715488C (en) | Immunogenic control of tumours and tumour cells | |
| US20020044948A1 (en) | Methods and compositions for co-stimulation of immunological responses to peptide antigens | |
| AU2006299106A1 (en) | Compositions and methods for treating tumors presenting survivin antigens | |
| AU2003224819A1 (en) | Epitope constructs comprising antigen presenting cell targeting mechanisms | |
| JP2000502052A (ja) | 腫瘍ワクチン及びその製造方法 | |
| US20070048860A1 (en) | Carcinoembryonic antigen (CEA) peptides | |
| WO2009002418A2 (en) | T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof | |
| WO1999063945A2 (en) | Vaccination strategy to prevent and treat cancers | |
| WO2001041741A9 (en) | Hla class i a2 tumor associated antigen peptides and vaccine compositions | |
| EP2576613A1 (de) | Her-2-peptide und impfstoffe | |
| Hermans et al. | Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge | |
| MXPA02008219A (es) | Peptidos que enlazan hla y sus usos. | |
| Sherman et al. | Strategies for tumor elimination by cytotoxic T lymphocytes | |
| Le Gal et al. | Lipopeptide‐based melanoma cancer vaccine induced a strong MART‐27‐35‐cytotoxic T lymphocyte response in a preclinal study | |
| Hurpin et al. | The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity | |
| CA3031725A1 (en) | Lmp1-expressing cells and methods of use thereof | |
| Stevenson et al. | Tumor vaccines | |
| US20040131598A1 (en) | Cancer therapy | |
| Swiniarski et al. | Immune response enhancement by in vivo administration of B7. 2Ig, a soluble costimulatory protein | |
| uben Dyall et al. | Heteroclitic Immunization Induces Tumor Immunity | |
| US20020132976A1 (en) | Immunogenic peptides derived from prostate-specific antigen (PSA) and uses thereof | |
| Ngo-Giang-Huong et al. | Mutations in residue 61 of H-Ras p21 protein influence MHC class II presentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010110 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE DK FR GB IE LI NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20020604 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE DK FR GB IE LI NL SE |
|
| 17Q | First examination report despatched |
Effective date: 20040123 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20060118 |